Report Sections

See All Reports

Coronavirus Infections (787) Severe Acute Respiratory Syndrome (538) Infection (447) Pneumonia (358) Communicable Diseases (191) Respiratory Distress Syndrome, Adult (179) Acute Lung Injury (142) Respiratory Distress Syndrome, Newborn (141) (127) Syndrome (123) Virus Diseases (88) Depression (78) Pneumonia, Viral (77) Critical Illness (67) Anxiety Disorders (49) Disease (40) Respiratory Tract Infections (38) Neoplasms (36) Stress Disorders, Post-Traumatic (36) Wounds and Injuries (35) Emergencies (34) Cardiovascular Diseases (33) Diabetes Mellitus (33) Inflammation (33) Stress Disorders, Traumatic (31) Stress, Psychological (30) Depressive Disorder (29) Lung Injury (29) Acute Kidney Injury (27) Respiratory Tract Diseases (27) Hypoxia (26) Mental Disorders (26) Thrombosis (25) Hypertension (24) Lung Diseases (24) Influenza, Human (22) Disease Progression (21) Olfaction Disorders (20) Arthritis (19) Respiration Disorders (19) Sclerosis (19) Burnout, Psychological (18) Diabetes Mellitus, Type 2 (18) Embolism (18) Fibrosis (18) Multiple Sclerosis (18) Thromboembolism (18) HIV Infections (16) Pulmonary Embolism (16) Respiratory Aspiration (16) Stroke (16) Blood Coagulation Disorders (15) Cognitive Dysfunction (15) Hemostatic Disorders (15) Pulmonary Disease, Chronic Obstructive (15) Pulmonary Fibrosis (15) Arthritis, Rheumatoid (14) Autism Spectrum Disorder (14) Chronic Disease (14) Heart Diseases (14) Kidney Diseases (14) Lung Diseases, Interstitial (14) Lung Diseases, Obstructive (14) Asthma (13) Brain Injuries (13) Chronic Pain (13) Myocardial Infarction (13) Substance-Related Disorders (13) Heart Failure (12) Lung Neoplasms (12) Venous Thrombosis (12) Autistic Disorder (11) Colitis (11) Colitis, Ulcerative (11) Crohn Disease (11) Dyspnea (11) Infarction (11) Obesity (11) Ulcer (11) Diabetes Mellitus, Type 1 (10) Pregnancy Complications (10) Rheumatic Diseases (10) Brain Injuries, Traumatic (9) Burnout, Professional (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Depression, Postpartum (9) Feeding and Eating Disorders (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Myocarditis (9) Parkinson Disease (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency, Chronic (9) Respiratory Syncytial Virus Infections (9) Alzheimer Disease (8) Carcinoma (8) Collagen Diseases (8) Dementia (8) Frailty (8) Hematologic Neoplasms (8) Ischemia (8) Overweight (8) Problem Behavior (8) Psychotic Disorders (8) Sepsis (8) Venous Thromboembolism (8) Vitamin D Deficiency (8) Alcoholism (7) Convalescence (7) Coronary Disease (7) Infertility (7) Kidney Failure, Chronic (7) Musculoskeletal Pain (7) Myocardial Ischemia (7) Parasomnias (7) Spinal Cord Injuries (7) Acute Coronary Syndrome (6) Alcohol Drinking (6) Breast Neoplasms (6) Child Development Disorders, Pervasive (6) Deglutition Disorders (6) Dyssomnias (6) Fatigue (6) Immune System Diseases (6) Leukemia (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Lymphopenia (6) Neurologic Manifestations (6) Osteoarthritis (6) Pediatric Obesity (6) Psoriasis (6) RNA Virus Infections (6) Renal Insufficiency (6) Shock (6) Autoimmune Diseases (5) Brain Diseases (5) Bronchiectasis (5) Carcinoma, Non-Small-Cell Lung (5) Colorectal Neoplasms (5) Coronaviridae Infections (5) Delirium (5) Depressive Disorder, Major (5) Disease Susceptibility (5) Fibromyalgia (5) Gastroparesis (5) Hypersensitivity (5) Immunologic Deficiency Syndromes (5) Metabolic Syndrome (5) Mobility Limitation (5) Multiple Organ Failure (5) Neoplasm Metastasis (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) (5) Premature Birth (5) Prostatic Neoplasms (5) Schizophrenia (5) Sleep Apnea Syndromes (5) Sleep Apnea, Obstructive (5) Toxemia (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Adenoviridae Infections (4) Anemia, Sickle Cell (4) Appendicitis (4) Arthritis, Psoriatic (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Coinfection (4) Colonic Neoplasms (4) Cross Infection (4) Death (4) Dermatitis (4) Disseminated Intravascular Coagulation (4) Embolism and Thrombosis (4) Endometriosis (4) Head and Neck Neoplasms (4) Heart Arrest (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Malnutrition (4) Metabolic Diseases (4) Migraine Disorders (4) Mycobacterium Infections (4) Pancreatic Neoplasms (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Weight Loss (4) Amyotrophic Lateral Sclerosis (3) Arrhythmias, Cardiac (3) Asymptomatic Diseases (3) Carcinoma, Renal Cell (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Dermatitis, Atopic (3) Developmental Disabilities (3) Digestive System Diseases (3) Dysgeusia (3) Eczema (3) Fatigue Syndrome, Chronic (3) Fever (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Headache (3) Heart Defects, Congenital (3) Hemophilia A (3) Huntington Disease (3) Hypothermia (3) Idiopathic Pulmonary Fibrosis (3) Leukemia, Lymphoid (3) Macular Edema (3) Measles (3) Melanoma (3) Motor Neuron Disease (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Sclerosis, Relapsing-Remitting (3) (3) Neuroendocrine Tumors (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Sleep Wake Disorders (3) Spondylarthritis (3) Taste Disorders (3) Ventricular Dysfunction (3) Ventricular Dysfunction, Left (3) Acute Disease (2) Ageusia (2) Agoraphobia (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Apnea (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Back Pain (2) Bacteremia (2) Bacterial Infections (2) Behcet Syndrome (2) Bipolar Disorder (2) Caliciviridae Infections (2) Cataract (2) Clinical Deterioration (2) Clostridium Infections (2) Cognition Disorders (2) Communicable Diseases, Emerging (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Congenital Abnormalities (2) Conjunctivitis (2) Diabetic Nephropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Endocrine System Diseases (2) Eye Diseases (2) Fatty Liver (2) Fistula (2) Fractures, Stress (2) Ganglion Cysts (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hematologic Diseases (2) Hepatitis (2) Hepatitis A (2) Hepatitis C (2) Hyperglycemia (2) Hyperkinesis (2) Hyperphagia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid, Acute (2) Liver Failure (2) Low Back Pain (2) Lymphedema (2) Lymphoproliferative Disorders (2) Macular Degeneration (2) Meningitis (2) Meningitis, Meningococcal (2) Mood Disorders (2) Multiple Myeloma (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myelodysplastic Syndromes (2) Myeloproliferative Disorders (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Non-alcoholic Fatty Liver Disease (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obesity, Morbid (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Pain, Postoperative (2) Pancreatitis (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) (2) Scleroderma, Systemic (2) Shock, Septic (2) Small Cell Lung Carcinoma (2) Spinal Diseases (2) Sprains and Strains (2) Stillbirth (2) Suicidal Ideation (2) Suicide (2) Tachycardia (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Trauma and Stressor Related Disorders (2) Tuberculosis (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Yellow Fever (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Acute Lung Injur (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia, Aplastic (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Anorexia (1) Anorexia Nervosa (1) Aortic Valve Stenosis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Bronchitis (1) Bronchitis, Chronic (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bruxism (1) Bulimia (1) Calculi (1) Carcinoma, Hepatocellular (1) Carcinoma, Ovarian Epithelial (1) Carcinoma, Small Cell (1) Carcinoma, Squamou (1) Carcinoma, Squamous Cell (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colonic Diseases (1) (1) Communication Disorders (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Cough (1) Coxsackievirus Infections (1) Cryopyrin-Associated Periodic Syndromes (1) (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) Depressive Disorder, Treatment-Resistant (1) DiGeorge Syndrome (1) Diabetic Foot (1) Diabetic Neuropathies (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epilepsy (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Genetic Predisposition to Disease (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperphosphatemia (1) Hyperplasia (1) Hypersensitivity, Immediate (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infect (1) Infecti (1) Infertility, Female (1) Infertility, Male (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratosis (1) Keratosis, Actinic (1) Kidney Calculi (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Lymphocytic, Chronic, B-Cell (1) Leukemia, Myeloid (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Liver Cirrhosis, Biliary (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Mantle-Cell (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Menorrhagia (1) Menstruation Disturbances (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Mucositis (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Orbital Cellulitis (1) Oropharyngeal Neoplasms (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Paresis (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Diseases (1) Peripheral Nervous System Diseases (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Pneumonia, Bacterial (1) Polyps (1) Pregnancy in Diabetics (1) Preleukemia (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Rabies (1) Radiculopathy (1) Rectal Neoplasms (1) Reperfusion Injury (1) Respiratory Distress Syndrom (1) Respiratory Distress Syndrome, Newbor (1) Respiratory Hypersensitivity (1) Retinal Vein Occlusion (1) Sarcoidosis, Pulmonary (1) Sarcopenia (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylolisthesis (1) Status Epilepticus (1) Stomatitis (1) Stress Disorders (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Tachycardia, Sinus (1) Tachycardia, Ventricular (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Neoplasms (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D000070642: Brain Injuries, Traumatic

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO

Correlated Drug Terms (27)

Name (Synonyms) Correlation
drug911 Chloroquine or hydroxychloroquine Wiki 0.47
drug912 Chloroquine phosphate Wiki 0.38
drug4484 fMRI Wiki 0.33
Name (Synonyms) Correlation
drug627 Brain Health Education (BHE) Wiki 0.33
drug392 Attention Control Group Wiki 0.33
drug1660 Group Lifestyle Balance™ Wiki 0.33
drug2805 Pacing + mindfulness Wiki 0.33
drug4814 zinc Wiki 0.33
drug3103 Prolonged Exposure (PE) Wiki 0.33
drug844 Cannabis, Medical Wiki 0.33
drug4466 eM2M Wiki 0.33
drug3752 Standard supportive care Wiki 0.33
drug3299 Reconsolidation of Traumatic Memories (RTM) Wiki 0.33
drug1645 Goal-Oriented Attentional Self-Regulation (GOALS) Wiki 0.33
drug898 Chest physiotherapy using a non-invasive oscillating device Wiki 0.33
drug2525 Negative Ion Generator Wiki 0.33
drug1439 Exercise Testing and Training Wiki 0.33
drug2434 Morning Bright Light Therapy Wiki 0.33
drug1647 Graded exposure therapy Wiki 0.33
drug907 Chloroquine Sulfate Wiki 0.24
drug492 BNT162b1 Wiki 0.19
drug918 Cholecalciferol Wiki 0.17
drug3928 Telemedicine Wiki 0.17
drug904 Chloroquine Wiki 0.13
drug3319 Remdesivir Wiki 0.06
drug1775 Hydroxychloroquine Wiki 0.03
drug2916 Placebo Wiki 0.01

Correlated MeSH Terms (35)

Name (Synonyms) Correlation
D001930 Brain Injuries, NIH 0.83
D001924 Brain Concussion NIH 0.33
D016135 Spinal Dysraphism NIH 0.33
Name (Synonyms) Correlation
D000070627 Chronic Traumatic Encephalopathy NIH 0.33
D013226 Status Epilepticus NIH 0.33
D002543 Cerebral Hemorrhage NIH 0.33
D013345 Subarachnoid Hemorrhage NIH 0.33
D005879 Tourette Syndrome NIH 0.33
D001714 Bipolar Disorder NIH 0.24
D014947 Wounds and Injuries NIH 0.23
D010300 Parkinsonian NIH 0.22
D000690 Amyotrophic Lateral Sclerosis NIH 0.19
D012640 Seizures NIH 0.19
D002547 Cerebral Palsy NIH 0.19
D016472 Motor Neuron Disease NIH 0.19
D059350 Chronic Pain NIH 0.18
D000755 Anemia, Sickle Cell NIH 0.17
D013313 Stress Disorders, Post-Traumatic NIH 0.17
D006470 Hemorrhage NIH 0.17
D009103 Multiple Sclerosis NIH 0.16
D005356 Fibromyalgia NIH 0.15
D001927 Brain Diseases NIH 0.15
D013119 Spinal Cord Injuries NIH 0.13
D059352 Musculoskeletal Pain NIH 0.13
D040921 Stress Disorders, Traumatic NIH 0.12
D015212 Inflammatory Bowel Diseases NIH 0.11
D004194 Disease NIH 0.11
D003424 Crohn Disease NIH 0.10
D020521 Stroke NIH 0.08
D012598 Scoliosi NIH 0.08
D013577 Syndrome NIH 0.03
D003141 Communicable Diseases NIH 0.02
D007239 Infection NIH 0.02
D045169 Severe Acute Respiratory Syndrome NIH 0.01
D018352 Coronavirus Infections NIH 0.01

Correlated HPO Terms (14)

Name (Synonyms) Correlation
HP:0002133 Status epilepticus HPO 0.33
HP:0002138 Subarachnoid hemorrhage HPO 0.33
HP:0001342 Cerebral hemorrhage HPO 0.33
Name (Synonyms) Correlation
HP:0002414 Spina bifida HPO 0.33
HP:0100754 Mania HPO 0.24
HP:0006802 Abnormal anterior horn cell morphology HPO 0.19
HP:0001264 Spastic diplegia HPO 0.19
HP:0007354 Amyotrophic lateral sclerosis HPO 0.19
HP:0012532 Chronic pain HPO 0.18
HP:0001250 Seizure HPO 0.17
HP:0001298 Encephalopathy HPO 0.15
HP:0002037 Inflammation of the large intestine HPO 0.11
HP:0100280 Crohn's disease HPO 0.10
HP:0001297 Stroke HPO 0.08

Clinical Trials

Navigate: Correlations   HPO

There are 9 clinical trials

1 Multi-Level Assessment and Rehabilitation of Combat Mild TBI

One of the most pressing concerns within the VA currently is the provision of interventions that address the cognitive as well as emotional problems faced by Veterans with mild TBI and comorbid conditions. When completed, these studies will inform us whether training core attentional self-regulatory control functions via personally-relevant activities will be effective in improving daily life for Veterans with mild TBI and comorbid conditions. The study design will provide a test not only of potential benefits for real life functioning, but also determine to what extent these benefits are related to actual changes in cognitive/behavioral performance and brain networks corresponding to these functions. This project will provide a foundation for future studies to investigate the neural mechanisms that support improvements of cognition and behavior in mTBI.

  1. Brain Injuries, Traumatic
  1. Behavioral: Goal-Oriented Attentional Self-Regulation (GOALS)
  2. Other: Brain Health Education (BHE)
  3. Device: fMRI
MeSH:Brain Injuries Brain Injuries, Traumatic

Primary Outcomes

Description: Single Test for Attention, Executive Function and Mental Flexibility

Measure: Delis-Kaplan Executive Function System (D-KEFS) Stroop Inhibition-Switching Task

Time: 6 months after enrollment
2 Neurobiological and Psychological Benefits of Exercise in Chronic Pain and PTSD

The wars in Iraq and Afghanistan are creating a new generation of Veterans, including an increasing number of women Veterans, who present with comorbid PTSD and chronic pain conditions from recent deployment-related physical injuries and exposure to psychological trauma. Health behavior change has become increasingly important in treating these conditions and proactively preventing long-term negative health sequelae, in order to benefit these Veterans directly and reduce the growing challenges to our healthcare system. The proposed CDA-2 program of research will use an innovative translational research approach to study whether a chronic progressive -based exercise program will reduce chronic pain in patients with PTSD and to elucidate and modify potential PTSD-related deficiencies in neurobiological and psychological responses to exercise to optimize the physical and psychological benefits of exercise for these individuals.

  1. Chronic Musculoskeletal Pain
  2. Posttraumatic Stress Disorder (PTSD)
  3. Mild or Moderate Traumatic Brain Injury
  1. Behavioral: Exercise Testing and Training
MeSH:Musculoskeletal Pain Brain Injuries Brain Injuries, Traumatic Chronic Pain Stress Disorders, Post-Traumatic
HPO:Chronic pain

Primary Outcomes

Description: To be administered at: Screening Evaluation & Endpoint 13 week exercise test sessions This 30-item structured interview is designed to assess both the 17 symptoms of PTSD and the 8 hypothesized associated features. The scale yields a dichotomous diagnosis of PTSD, and also provides a continuous score of frequency and severity for each symptom. In addition, a behaviorally anchored probe question is provided for each symptom to increase the reliability of administration. The CAPS-5 is currently in the process of being validated however its previous version demonstrated excellent sensitivity (.81) and specificity (.95).57

Measure: Change from Baseline: Clinician Administered PTSD Scale -5

Time: Baseline and endpoint (at 13 weeks)

Description: The WHY-MPI has been demonstrated to be applicable across a variety of clinical pain conditions. Its brevity, validity/ reliability, self-report nature and ease of scoring make it ideal for both clinical and research purposes. The WHY-MPI is sensitive to change following rehabilitation. Please note only the interference subscale of the WHY-MPI will be administered in this study.

Measure: Change from Baseline: West Haven=Yale Multidimensional Pain Inventory- Interference Subscale (WHY-MPI)

Time: Baseline, Midpoint (at 6 weeks) and Endpoint (at 13 weeks)
3 Efficacy of an Evidence-based Weight-loss Intervention Post Traumatic Brain Injury

The purpose of this RCT is to examine the efficacy of a Group Lifestyle Balance™ (GLB) program adapted for people with traumatic brain injury (TBI) on primary (weight) and secondary outcomes at 3, 6, 12, and 18 months from enrollment into the program.

  1. Traumatic Brain Injury
  1. Behavioral: Group Lifestyle Balance™
  2. Other: Attention Control Group
MeSH:Brain Injuries Brain Injuries, Traumatic Wounds and Injuries

Primary Outcomes

Description: Weight will be obtained using the same scale over the study period that is accessible to people with and without a mobility device (e.g. walker; wheelchair)

Measure: Change in weight

Time: Baseline, 3 months, 6, months, 12 months, and 18 months

Secondary Outcomes

Description: The Garmin Vivofit will be worn for the study duration to measure physical activity data.

Measure: Step Count

Time: 3 months, 6 months, 12 months, and 18 months

Description: Waist circumference will be measured at the umbilicus and mild-upper arm circumference following American College of Sports Medicine guidelines.

Measure: Waist and Arm Circumference

Time: Baseline, 3 months, 6 months, 12 months, and 18 months

Description: Using an automatic cuff (average of three readings, patient seated) diastolic and systolic scores will be recorded.

Measure: Blood Pressure

Time: Baseline, 3 months, 6 months, 12 months, and 18 months

Description: Fasting venous sample will be obtained for blood glucose, HDL/LDL, cholesterol, and triglyceride level.

Measure: HbA1c and Lipid Panel

Time: Baseline, 3 months, 6 months, 12 months, and 18 months

Description: The Framingham Heart Study diabetes risk score will be calculated using predictors including age, gender, fasting glucose, body mass index, HDL cholesterol and triglyceride levels, blood pressure, and parental history. Risk score calculator and regression model are free and used in GLB weight-loss trials. Each risk predictor is assigned points ranging from. Risk factors are combined and a total score is calculated, with higher scores designating greater 8-year risk.. The age range for this score is 45 years or older, and therefore only individuals over this age will have calculated scores. Furthermore, the minimum cut-off score is 3.

Measure: Risk of Diabetes

Time: Baseline, 3 months, 6 months, 12 months, and 18 months

Description: Satisfaction with life will be measured using the Satisfaction with Life Scale (SWLS). The SWLS is a 5-item scale designed to measure global cognitive judgements of one's life satisfaction. Participants indicate how much they agree or disagree with each of the 5 items using a 7-point scale that ranges from 7-strongly agree to 1-strongly disagree. Scores are added together and a total score is calculated, with higher scores signifying higher satisfaction with life and lower scores signifying lower satisfaction with life.

Measure: Satisfaction with Life

Time: Baseline, 3 months, 6 months, 12 months, and 18 months

Description: TSH, Cortisol, IL-6, THNF, BDNF, IGF, and VEGF will be collected.

Measure: Biomarkers

Time: Baseline, 3 months, 6 months, 12 months, and 18 months

Description: Assesses walking speed in (m/s) which is correlated to mobility in the community, capacity to perform ADLs, risk of falls, re-hospitalization, and risk of cognitive decline.

Measure: 10 Meter Walk Test (10MWT)

Time: Baseline, 3 months, 6 months, and 12 months

Description: Assesses distance walked (rolled for wheelchair users) over 6 minutes as a sub-maximal test of aerobic capacity.

Measure: 6 Minute Walk Test (6MWT)

Time: Baseline, 3 months, 6 months, and 12 months

Description: Social Support for Diet and Exercise Behaviors Scale is a 23-item survey including four subscales: support for healthy eating (5 items); support for physical activity (11 items); social undermining for healthy eating (5 items) and physical activity (2 items). Each item is rated on a scale of 1 to 5 (1 none; 5 very often), with respondents asked to rate support from family, friends, and coworkers. Higher scores represent greater support and internal consistency ranged from Cronbach's α 0.72-0.76.

Measure: Social Support assessed by the Social Support for Diet and Exercise Behaviors Scale

Time: Baseline, 3 months, 6 months, 12 months, and 18 months

Description: The Feasibility and Usability survey includes 14 items that assesses the participant's subjective experience with the App, level of difficulty, prompting sequence, length, and understanding. Scores above 3 on the scale (1 [totally disagree] - 5 [totally agree]) indicate that the App was easy to use.

Measure: App Feasibility and Usability using the Feasibility and Usability Survey

Time: 6 months, 12 months, and 18 months

Description: NEWS assesses residents' perception of neighborhood design features, categorized into subscales related to physical activity, including residential density, land use mix (including both indices of proximity and accessibility), street connectivity, infrastructure for walking/cycling, neighborhood aesthetics, traffic and crime safety, and neighborhood satisfaction. Subscales are scored as a mean of items. Higher scores denote higher walkability.

Measure: Neighborhood Walkability assessed by the Neighborhood Environment Walkability Scale (NEWS)

Time: Baseline and 12 months

Description: Measure includes 28 items that assess health practices among people with disabilities and yields a total Health Practices score plus 4 subscales scores regarding Exercise, Nutrition, Health Practices, and Psychological Well Being. Items are rated on a 5-point scale from 0 'not at all' to 4 'completely.' Scores range from 0-28 with higher scores indicating higher exercise self-efficacy.

Measure: Self-Reported Activities of Health using the Self-Reported Activities of Health for Health Promotion Scale

Time: Baseline, 12 months, and 18 months

Description: This inventory consists of 40 life events and asks the participant to recall if any of the events happened within the previous year (e.g., death of spouse; personal illness; change in sleep). Endorsement of these events are totaled and higher scores indicate a greater amount of stressful life events. Point values for the Holmes and Rahe Stress Inventory were weighted and summed for each individual based on scoring instructions. Individuals who scored 150 points or less were categorized as low susceptibility to a health breakdown in the next two years, 151-300 points were 50% chance of health breakdown, and 301 points or more were 80% chance of health breakdown.

Measure: Stressful Life Events assessed by the Holmes and Rahe Stress Inventory

Time: Baseline, 3 months, 6 months, 12 months, and 18 months

Description: The GLB TBI/Attention Control groups will both use this app. Usage and engagement will be collected.

Measure: App Data

Time: 6 months, 12 months, and 18 months

Description: The MOCA is a brief, 8-section assessment of various cognitive domains including executive function, memory, language, attention, concentration, orientation, and working memory in neurologic populations. Each item on the MOCA is allocated a set of points adding up to 30.

Measure: Executive Function assessed by the Montreal Cognitive Assessment

Time: Baseline, 3 months, and 12 months

Description: Self-Report Habit Index measures self-reported perceptions of habit strength for an identified behavior. The measure has high internal reliability across four studies. The measure consists of 12 items using a 7-point Likert scale ranging from "completely disagree" to "completely agree", with higher scores representing greater perception of habit strength.

Measure: Self-reported perceptions of habit strength assessed by the Self-Report Habit Index (SRHI)

Time: Baseline, 3 months, and 12 months

Description: The PHQ-8 is a brief self-report measure of major depressive disorder, derived from the PHQ-9 by removing the last question regarding suicide assessment.It is considered to be a valid measure of depression for population-based studies and clinical populations, and has been used in studies of patients with physical injury. Frequency of symptoms during the last 2 weeks is assessed on a 0 (not at all) to 3 (nearly every day) scale. A cut-off score of 10 or greater is considered diagnostic for current depression

Measure: Depression assessed using the Patient Health Questionnaire-8 item

Time: Baseline, 12 months, and 18 months

Description: Walk Score is publically available and measures walkability of any address using a patented system. Fore each address, Walk Score analyzes hundreds of walking routes to nearby amenities and awards points based on distance to each amenities. Scores are given on a scale of 0 to 100.

Measure: Walk Score

Time: Baseline and 12 months

Description: The BAST is a 47 item, theoretically grounded, validated survey of behavioral and emotional symptoms for community-based adults with TBI. This assessment is a shortened version of the validated 77-item survey, with questions related to environmental stressors and mood removed due to repetitiveness to other questions in survey packet. Responses are asked over the past two weeks using an ordinal scale from 0 "rarely" to 5 "very often." There are 6 subscales: Negative Affect, Substance Use, Executive Function, Fatigue, Impulsivity, and Maladaptive Coping. Higher scores indicate more symptoms in those domains. This measure will be used to characterize behavioral/emotional symptoms and to explore whether these are factors that influence

Measure: Behavioral Assessment

Time: Baseline and 6 months

Description: The ten items from the General Self-Efficacy Scale (GSE) are deigned to examine goal-setting, effort investment, persistence in face of barriers and recovery from setbacks as constructs of perceived self-efficacy. The total score is the sum ranging from 10-40 and the instrument has been normed against the U.S. Adult population with a mean score of 29.48.

Measure: General Self Efficacy

Time: Baseline, 12 months, and 18 months

Description: The BRFSS is a state-based system of health surveys that collects information on health risk behaviors, preventative health practices, and health care access primarily related to chronic disease and injury. The GLB-TBI uses the two subscales of Healthy Eating and Physical Activity from the 2017 version of the BRFSS. It consists of 14 items.

Measure: Behavioral Risk Factor Surveillance

Time: Baseline, 3, 6, 12, and 18 months.

Description: This is an FDA cleared and validated indirect calorimetry device. It is handheld and measures oxygen consumption (V02) to determine resting metabolic rate (RMR)

Measure: MedGem

Time: Baseline

Description: The metabolic score calculator will be used at all time points to determine the risk for metabolic syndrome. The following variables will be used to determine metabolic risk using the free metabolic risk calculator: gender, race and ethnicity, systolic blood pressure, fasting glucose, triglycerides, high-density lipoprotein (HDL), weight, height, and waist circumference. Scores are calculated are standardized to the general population.

Measure: Metabolic Score Calculator (MetS)

Time: Baseline, 3, 6, 12, and 18 months

Description: Information on substance use will be collected using the AUDIT-C (for alcohol use) and three questions regarding tobacco and non-prescriptive drug use.

Measure: Substance Use

Time: Baseline, 12 months

Description: This self-report survey was developed by the National Institute of Mental Health. The full survey consists of 64 questions with an open-ended section at the end to elicit concerns and feedback related to the effects of COVID-19. For this current study, however, only sections on Exposure Status (10 items), Life Changes (15 items), and Emotions/Worries (7 items), and the open-ended question will be asked. Questions are asked "over the past two weeks."

Measure: CRISIS (CoRonavIruS Health Impact Survey) V0.3 Adult Baseline Form

Time: Up to 12 months

Description: The Social Isolation Short-Form 4a is taken from the Patient-Reported Outcomes Measurement Information System (PROMIS). This form assesses the perceptions of being "avoided, excluded, detached, disconnected from, or unknown by, others. There is no timeframe for the form. The measure is normed to the US population.

Measure: PROMIS Social Isolation Short Form 4a

Time: Up to 12 months

Description: To assess media exposure and fear of media exposure during COVID-19 we have added 6 questions. These are asked "over the past two weeks." These questions address time spent watching the television, listening to radio, reading the newspaper, and searching the internet and social media. In addition, a 6th question related to fear is asked using a 5-point Likert scale.

Measure: Media Questionnaire

Time: Up to 12 months
4 A Sleep Intervention to Improve Rehabilitation in Veterans With Chronic mTBI

Traumatic brain injury (TBI) is a major cause of disability in the Veteran population, often resulting in chronic pain and sleep disturbances, among other issues. Extensive rehabilitative efforts are usually required and often prevent return to the workforce and community. Disturbed sleep and excessive daytime sleepiness are among the most pervasive and enduring problems after TBI, which the investigators hypothesize is a significant contributor to these functional impairments and an impediment toward rehabilitation. Thus, this research aims to enhance sleep quality as a means to reduce pain and improve quality of life and functional outcome measures in Veterans with TBI. The investigators predict that the proposed intervention, morning bright light therapy, if found effective, will be cost-effective, rapidly deployable, and highly accepted by Veterans with TBI.

  1. Traumatic Brain Injury
  1. Device: Morning Bright Light Therapy
  2. Device: Negative Ion Generator
MeSH:Brain Injuries Brain Injuries, Traumatic

Primary Outcomes

Description: NIH PROMIS Pain Scale 4 questions; each question is a 0-4 scale, total score range is 0-16 Higher scores represent worse outcomes

Measure: self-reported pain change determined via the NIH PROMIS scale

Time: Pre- and post-4 weeks of MBLT or sham treatment, and 12 weeks following the end of MBLT or sham treatment
5 The M2M LEADERS Project: Lakeshore Examination of Activity, Disability, and Exercise Response Study (LEADERS)

The purpose of this study is to test the effects of an innovative exercise program referred to as movement-2-music (M2M) on health and fitness outcomes in adults with physical/mobility disabilities. One hundred and eight participants with physical/mobility disabilities will be recruited and randomly enrolled into one of two groups: a) M2M or b) waitlist control. The primary aim of this study is to determine the effects of a 12-week M2M program on health and fitness in participants with physical/mobility disabilities who are in one of three functional mobility groups: 1) Group I - only able to exercise while sitting, 2) Group II - able to exercise sitting and standing with/without support, and 3) Group III - able to exercise one side of the body more than the other side. The second aim is to compare the observed effects of the program in this study to a previous M2M study that groups participants based on disability type. The third aim of this study is to test whether adherence (defined as attendance to the 12-week program) affects the effects of M2M in participants with physical/mobility disabilities. The potential influences of different functional mobility and disabilities of participants on how the program affects participants' health and fitness outcomes will also be tested. **In response to COVID-19, the 12-week M2M intervention and all assessments have been modified from being delivered in-person at Lakeshore Foundation to being delivered remotely in real-time through videoconferencing technology.**

  1. Spinal Cord Injuries
  2. Traumatic Brain Injury
  3. Spina Bifida
  4. Cerebral Palsy
  5. Stroke
  6. Parkinson Disease
  7. Multiple Sclerosis
  1. Other: eM2M
MeSH:Parkinson Disease Multiple Sclerosis Brain Injuries Spinal Cord Injuries Brain Injuries, Traumatic Cerebral Palsy Spinal Dysraphism Wounds and Injuries
HPO:Athetoid cerebral palsy Cerebral palsy Spastic diplegia Spina bifida

Primary Outcomes

Description: The cardiorespiratory fitness is measured using a heart rate recovery test

Measure: Change from baseline cardiorespiratory fitness at 3 months

Time: Baseline and post 12-week intervention

Description: Muscle strength is measured with grip strength using a hand-held dynamometer.

Measure: Change from baseline muscle strength at 3 months

Time: Baseline and post 12-week intervention

Secondary Outcomes

Description: Lower extremity function is assessed using the Short Physical Performance Battery (SPPB)

Measure: Change from baseline lower extremity function at 3 months

Time: Baseline and post 12-week intervention

Description: Lower extremity function will be assessed using the Timed Up and Go (TUG) test.

Measure: Change from baseline lower extremity function at 3 months

Time: Baseline and post 12-week intervention

Description: Health-related quality of life is measured using the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 Health Items. The instrument is a 10-item measure with the response scores ranging from 1 (very severe) to 5 (none). Two summary scores, a global physical health score and a global mental health score, can be calculated from this scale, with each score ranging from 4 to 20. Higher scores indicate better health. The total raw score is translated into a T-score for each participant for analysis.

Measure: Change from baseline health-related quality of life at 3 months

Time: Baseline and post 12-week intervention

Description: Social participation is measured using the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities. The instrument is a 8-item measure with the response scores ranging from 1 (always) to 5 (never). The lowest possible total raw score is 8 and the highest possible score is 40. Higher scores indicate better ability to participate in social roles and activities. The total raw score is translated into a T-score for each participant for analysis.

Measure: Change from baseline social participation at 3 months

Time: Baseline and post 12-week intervention

Description: Physical activity is measured using the Godin Leisure Time Exercise Questionnaire. The questionnaire contains two questions. The first question asks participants to report weekly frequencies of activities they perform at different intensities. A total weekly leisure activity is a sum of activity scores calculated by multiplying the weekly frequencies of strenuous, moderate, and light activities by 9, 5, and 3, respectively. The second question asks participants the frequency of weekly leisure-time activities performed that are long enough to work up a sweat.

Measure: Change from baseline physical activity at 3 months

Time: Baseline and post 12-week intervention

Other Outcomes

Description: Barriers in physical activity will be assessed using the Barriers in Physical Activity Questionnaire. The instrument contains 43 items. Each item is responded with either no (1) or yes (2). If response is yes, a follow-up response that ranges from 1 (very small) to 5 (very large) is selected. There are 8 domains, which include personal health, attitudes/beliefs towards physical activity, friends, family, fitness center built environment, policy/programs/staff, community built environment, and safety. Each domain score is calculated by summing the item responses with its respective item weight. Higher domain scores indicate greater perceived barriers to physical activity.

Measure: Change from baseline barriers in physical activity at 3 months

Time: Baseline and post 12-week intervention

Description: Exercise self-efficacy will be assessed using the Exercise Self-Efficacy Scale. The scale contains 8 items, with response options of each item ranging from 0% (not at all confident) to 100% (highly confident). All items are summed and a mean score is calculated. Higher scores indicate higher levels of self-efficacy.

Measure: Change from baseline exercise self-efficacy at 3 months

Time: Baseline and post 12-week intervention

Description: Exercise goal-setting will be measured using the Exercise Goal-Setting Scale. The instrument contains 10 items with response options ranging from 1 (does not describe) to 5 (describes completely). A mean score is calculated. A higher mean score indicate better goal-setting and self-monitoring for exercise.

Measure: Change from baseline exercise goal-setting at 3 months

Time: Baseline and post 12-week intervention

Description: Outcome expectations for exercise will be assessed using the Multidimensional Outcome Expectations for Exercise Scale. The instrument contains 15 items, with the response options ranging from 1 (strongly disagree) to 5 (strongly agree). Three domains of outcome expectations for exercise are assessed, which include physical outcome expectations (6 items), social outcome expectations (4 items), and self-evaluative outcome expectations (5 items). Each dimension is scored by summing the item responses. Higher scores indicate higher levels of outcome expectations for exercise.

Measure: Change from baseline outcome expectations for exercise at 3 months

Time: Baseline and post 12-week intervention

Description: Social support will be assessed using the Social Provision Scale. The instrument contains 24 items, with the response options ranging from 1 (strongly disagree) to 4 (strongly agree). A total score is calculated by summing scores from all items. A higher score indicates a greater degree of perceived support.

Measure: Change from baseline social support at 3 months

Time: Baseline and post 12-week intervention
6 RECONsolidation of Traumatic Memories to ResOLve Post Traumatic Stress Disorder (RECONTROLPTSD)

Posttraumatic Stress Disorder (PTSD) is a common cause of morbidity in combat veterans, but current treatments are often inadequate. Reconsolidation of Traumatic Memories (RTM) is a novel treatment that seeks to alter key aspects of the target memory (e.g., color, clarity, speed, distance, perspective) to make it less impactful, and reduce nightmares, flashbacks, and other features of PTSD. The memory is reviewed in the context of an imaginal movie theater, presenting a fast (~45 sec) black and white movie of the trauma memory, with further adjustment as needed so the patient can comfortably watch it. Open and waitlist studies of RTM have reported high response rates and rapid remission, setting the stage for this randomized, controlled, single-blind trial comparing RTM versus prolonged exposure (PE), the PTSD therapy with the strongest current evidence base. The investigators hypothesize that RTM will be non-inferior to PE in reducing PTSD symptom severity post-treatment and at 1-year follow up; will achieve faster remission, with fewer dropouts; will improve cognitive function; and that epigenetic markers will correlate with treatment response. The investigators will randomize 108 active or retired service members (SMs) with PTSD to ≤10 sessions of RTM or PE, affording power to test our hypotheses while allowing for ≤ 25% dropouts. The investigators will use an intent to treat analysis, and the Clinician Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, or DSM5 (CAPS-5), conducted by blinded assessors, will be the primary outcome measure. Secondary measures of depression (PHQ-9), anxiety (GAD-7), sleep (PSQI), and functional status (WHOQOL-100), will be assessed pre- and post-treatment, and at 2, 6, and 12 months. ANOVA will compare symptom severity over time within and between groups. Blood draws will be obtained pre- and posttreatment to assess predictors of treatment response and epigenetic markers of change. The NIH Toolbox Neurocognitive Assessment, pre- and post-treatment, will assess impact on cognitive function. The investigators will track comorbid TBI, anticipating it will not adversely impact response. More effective therapies for PTSD, with and without TBI, must be developed and evaluated. RTM is safe and promising, but requires testing against evidence-based interventions in well-designed randomized clinical trials (RCTs). The full study can now be conducted via video conferencing due to COVID-19.

  1. Posttraumatic Stress Disorder
  2. Traumatic Brain Injury
  1. Behavioral: Reconsolidation of Traumatic Memories (RTM)
  2. Behavioral: Prolonged Exposure (PE)
MeSH:Brain Injuries Brain Injuries, Traumatic Disease Stress Disorders, Traumatic Stress Disorders, Post-Traumatic

Primary Outcomes

Description: the gold standard for PTSD diagnosis, a trained expert administrator scores PTSD symptom severity; range 0-80, higher score represents greater severity

Measure: Clinician Administered PTSD Symptom Scale for DSM5 (CAPS-5)

Time: week 10

Secondary Outcomes

Description: well-validated and widely used 9-item self-report measure of depression symptom severity, range 0-27, higher score represents greater severity

Measure: Change in Patient Health Questionnaire (PHQ-9) Score

Time: week 10, and 2, 6 and 12 months later, compared to baseline

Description: a reliable 20-item screen for PTSD, in which each item is rated on a 5-point Likert scale, range 0-80, higher score represents greater severity

Measure: Change in PTSD Checklist for DSM5 (PCL5) Score

Time: week 10, and 2, 6 and 12 months later, compared to baseline

Description: a clinically validated 9-item assessment of sleep quality and sleep disturbances; range 0 to 21, higher score represents greater severity

Measure: Change in Pittsburgh Sleep Quality Index (PSQI) Score

Time: week 10, and 2, 6 and 12 months later, compared to baseline

Description: a reliable 22-item self-report measure assessing functional status and post concussive symptoms, range 0-88, higher score represents greater severity

Measure: Change in Neurobehavioral Symptom Inventory (NSI) Score

Time: week 10, and 2, 6 and 12 months later, compared to baseline

Description: a reliable 100 item self-report inventory measuring overall quality of life in 8 dimensions; range 100 to 500, higher score represents greater severity

Measure: Change in World Health Organization Quality of Life Inventory (WHOQOL-100) Score

Time: week 10, and 2, 6 and 12 months later, compared to baseline

Other Outcomes

Description: inflammatory cytokine that increases with physical and psychological trauma, measured at the picogram per milliliter level, present in plasma at detectable levels in all individuals with the single molecule array (SIMOA) technology to be applied, but expected to decrease in response to intervention

Measure: Change in plasma tumor necrosis factor-alpha level

Time: week 10, compared to baseline

Description: inflammatory cytokine that increases with physical and psychological trauma, measured at the picogram per milliliter level, present in plasma at detectable levels in all individuals with the SIMOA technology to be applied, but expected to decrease in response to intervention

Measure: Change in plasma interleukin-6 level

Time: week 10, compared to baseline

Description: inflammatory cytokine that increases with physical and psychological trauma, measured at the picogram per milliliter level, present in plasma at detectable levels in all individuals with the SIMOA technology to be applied, but expected to decrease in response to intervention

Measure: Change in plasma interleukin-10 level

Time: week 10, compared to baseline

Description: Normalized Summary Score for a battery of 7 tests to measure various aspects of cognition including memory, executive function, attention span; normed for age, with a score of 50 being average, scores greater than 50 demonstrate greater than average cognitive function, and scores lower than 50 indicating lower than average cognitive function

Measure: Change in NIH Toolbox Cognition Battery (NIH-TB) Neurocognitive Assessment Composite Score

Time: week 10, compared to baseline
7 Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

  1. Chronic Pain
  2. Chronic Pain Syndrome
  3. Chronic Pain Due to Injury
  4. Chronic Pain Due to Trauma
  5. Fibromyalgia
  6. Seizures
  7. Hepatitis C
  8. Cancer
  9. Crohn Disease
  10. HIV/AIDS
  11. Multiple Sclerosis
  12. Traumatic Brain Injury
  13. Sickle Cell Disease
  14. Post Traumatic Stress Disorder
  15. Tourette Syndrome
  16. Ulcerative Colitis
  17. Glaucoma
  18. Epilepsy
  19. Inflammatory Bowel Diseases
  20. Parkinson Disease
  21. Amyotrophic Lateral Sclerosis
  22. Chronic Traumatic Encephalopathy
  23. Anxiety
  24. Depression
  25. Insomnia
  26. Autism
  27. Opioid-use Disorder
  28. Bipolar Disorder
  29. Covid19
  30. SARS-CoV Infection
  31. COVID-19
  32. Corona Virus Infection
  33. Coronavirus
  1. Drug: Cannabis, Medical
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Wounds and Injuries Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic
HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

Primary Outcomes

Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (

Measure: Prevention of COVID-19

Time: Five years

Description: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (

Measure: Treatment of COVID-19

Time: Five years

Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

Measure: Treatment of Symptoms

Time: Five years

Secondary Outcomes

Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

Measure: Cannabis Impact on Quality of Life

Time: Five years

Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

Measure: Cannabis Route and Dosing

Time: Five years

Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

Measure: Monitoring Adverse Events

Time: Five years
8 Behavioral Profile Matching: A Precision Medicine Approach to Concussion Rehabilitation

At least 1 in 5 people who sustain a concussion will have persistent symptoms and difficulties with daily activities. The researchers have identified two unhelpful coping styles following a concussion - avoidance and endurance. Individuals who engage in avoidance behavior may benefit from a different type of treatment than those who engage in endurance behavior. The researchers will evaluate whether assigning individuals to a specific psychologically-informed treatment tailored to their coping style is practical, acceptable, and beneficial for their recovery.

  1. Mild Traumatic Brain Injury
  1. Behavioral: Graded exposure therapy
  2. Behavioral: Pacing + mindfulness
MeSH:Brain Injuries Brain Injuries, Traumatic Brain Concussion

Primary Outcomes

Measure: World Health Organization Disability Assessment Schedule (WHODAS) 2.0 12-item

Time: Initial assessment, past 30 days.

Secondary Outcomes

Measure: Rivermead Postconcussion Symptom Questionnaire

Time: initial assessment, past 24 hours.
9 Severe Neurologic Injury Outcomes During COVID-19 Crisis

A prospective cohort minimal risk study to determine the impact of the COVID-19 crisis on outcomes of neurologically injured ICU patients.

  1. Sars-CoV2
  2. Severe Neurologic Injury
  3. Ischemic Stroke
  4. Hemorrhagic Stroke
  5. Intracerebral Hemorrhage
  6. Subarachnoid Hemorrhage
  7. Traumatic Brain Injury
  8. Status Epilepticus
MeSH:Stroke Brain Injuries Brain Injuries, Traumatic Subarachnoid Hemorrhage Cerebral Hemorrhage Status Epilepticus Hemorrhage Wounds and Injuries
HPO:Cerebral hemorrhage Status epilepticus Stroke Subarachnoid hemorrhage

Primary Outcomes

Measure: In-hospital Mortality

Time: At hospital discharge, approximately 1 month

Measure: 30-day mortality

Time: 30 days post-hospital discharge

Secondary Outcomes

Description: Care treatment such as ventilator use, intubation, and/or tracheostomy

Measure: Limitations of patient care- Frequency of care not being provided

Time: During In-hospital course, up to 1 month

Measure: Limitations of patient care- Conversion of DNR/DNI/CMO status

Time: During In-hospital course, up to 1 month

HPO Nodes


Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials

HPO Nodes


Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  


4,180 reports on interventions/drugs


691 reports on MeSH terms


263 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook